Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Quantitative Profiling of Platelet-Rich Plasma Indole Markers by Direct-Matrix Derivatization Combined with LC-MS/MS in Patients with Neuroendocrine Tumors.

van Faassen M, Bouma G, de Hosson LD, Peters MAM, Kats-Ugurlu G, de Vries EGE, Walenkamp AME, Kema IP.

Clin Chem. 2019 Nov;65(11):1388-1396. doi: 10.1373/clinchem.2019.305359. Epub 2019 Sep 24.

PMID:
31551315
2.

Use of selective serotonin reuptake inhibitors is associated with very low plasma-free serotonin concentrations in humans.

Peters MA, van Faassen M, de Jong WH, Bouma G, Meijer C, Walenkamp AM, de Vries EG, Oosting SF, Ruhé HG, Kema IP.

Ann Clin Biochem. 2019 Oct 10:4563219880567. doi: 10.1177/0004563219880567. [Epub ahead of print] No abstract available.

PMID:
31533444
3.

Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers.

Peters MAM, Meijer C, Fehrmann RSN, Walenkamp AME, Kema IP, de Vries EGE, Hollema H, Oosting SF.

Pathol Oncol Res. 2019 Sep 2. doi: 10.1007/s12253-019-00734-w. [Epub ahead of print]

PMID:
31478179
4.

Melatonin is not stored in platelets.

van Faassen M, Peters MAM, Walenkamp AM, de Vries EGE, Oosting SF, Kema IP.

Clin Chim Acta. 2019 Nov;498:17-20. doi: 10.1016/j.cca.2019.07.028. Epub 2019 Jul 26.

PMID:
31356792
5.

Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT.

de Hosson LD, van der Loo-van der Schaaf AM, Boellaard R, van Snick JH, de Vries EGE, Brouwers AH, Walenkamp AME.

Clin Nucl Med. 2019 Aug;44(8):612-619. doi: 10.1097/RLU.0000000000002640.

PMID:
31274606
6.

Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma.

Lassman AB, Aldape KD, Ansell PJ, Bain E, Curran WJ, Eoli M, French PJ, Kinoshita M, Looman J, Mehta M, Muragaki Y, Narita Y, Ocampo C, Roberts-Rapp L, Song M, Vogelbaum MA, Walenkamp AME, Wang TJC, Zhang P, van den Bent MJ.

J Neurooncol. 2019 Aug;144(1):205-210. doi: 10.1007/s11060-019-03222-y. Epub 2019 Jul 4.

PMID:
31273577
7.

Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT.

de Hosson LD, van der Loo-van der Schaaf AM, Boellaard R, van Snick JH, de Vries EGE, Brouwers AH, Walenkamp AME.

Clin Nucl Med. 2019 Jun 13. doi: 10.1097/RLU.0000000000002640. [Epub ahead of print]

PMID:
31205146
8.

Web-based personalised information and support for patients with a neuroendocrine tumour: randomised controlled trial.

de Hosson LD, Bouma G, Stelwagen J, van Essen H, de Bock GH, de Groot DJA, de Vries EGE, Walenkamp AME.

Orphanet J Rare Dis. 2019 Feb 28;14(1):60. doi: 10.1186/s13023-019-1035-3.

9.

Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study.

Brahm CG, den Hollander MW, Enting RH, de Groot JC, Solouki AM, den Dunnen WFA, Heesters MAAM, Wagemakers M, Verheul HMW, de Vries EGE, Pruim J, Walenkamp AME.

Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2404-2412. doi: 10.1007/s00259-018-4090-4. Epub 2018 Jul 21.

10.

False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET (18F-FDOPA-PET) performed for imaging of neuroendocrine tumors.

Berends AMA, Kerstens MN, Bolt JW, Links TP, Korpershoek E, de Krijger RR, Walenkamp AME, Noordzij W, van Etten B, Kats-Ugurlu G, Brouwers AH, van der Horst-Schrivers ANA.

Eur J Endocrinol. 2018 Aug;179(2):125-133. doi: 10.1530/EJE-18-0321. Epub 2018 Jun 6.

PMID:
29875288
11.

Self-monitoring physical activity with a smartphone application in cancer patients: a randomized feasibility study (SMART-trial).

Ormel HL, van der Schoot GGF, Westerink NL, Sluiter WJ, Gietema JA, Walenkamp AME.

Support Care Cancer. 2018 Nov;26(11):3915-3923. doi: 10.1007/s00520-018-4263-5. Epub 2018 May 21.

12.
13.

Use of Video-consultation is Feasible During Follow-up Care of Patients with a Neuroendocrine Tumour.

Bouma G, de Hosson LD, van Essen H, de Vries EGE, de Groot DJA, Walenkamp AME.

Clin Oncol (R Coll Radiol). 2018 Jun;30(6):396. doi: 10.1016/j.clon.2018.02.027. Epub 2018 Mar 3. No abstract available.

PMID:
29506774
14.

Towards optimal personalized diet and vitamin supplementation in NET patients.

de Hosson LD, Stelwagen J, Bouma G, Sijtema B, Huitema S, van Faassen HJR, de Bock GH, de Groot DJA, Campmans-Kuijpers MJE, Kema IP, de Vries EGE, Walenkamp AME.

Endocr Relat Cancer. 2018 Mar;25(3):L23-L26. doi: 10.1530/ERC-17-0549. No abstract available.

PMID:
29431642
15.

Predictors of adherence to exercise interventions during and after cancer treatment: A systematic review.

Ormel HL, van der Schoot GGF, Sluiter WJ, Jalving M, Gietema JA, Walenkamp AME.

Psychooncology. 2018 Mar;27(3):713-724. doi: 10.1002/pon.4612. Epub 2018 Jan 26.

16.

Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework.

de Hosson LD, van Veenendaal LM, Schuller Y, Zandee WT, de Herder WW, Tesselaar MET, Klümpen HJ, Walenkamp AME.

Ann Oncol. 2017 Dec 1;28(12):3022-3027. doi: 10.1093/annonc/mdx547. Review.

PMID:
29045525
17.

CXCR4 Ligands: The Next Big Hit?

Walenkamp AME, Lapa C, Herrmann K, Wester HJ.

J Nucl Med. 2017 Sep;58(Suppl 2):77S-82S. doi: 10.2967/jnumed.116.186874. Review.

18.

Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis.

van Linde ME, Brahm CG, de Witt Hamer PC, Reijneveld JC, Bruynzeel AME, Vandertop WP, van de Ven PM, Wagemakers M, van der Weide HL, Enting RH, Walenkamp AME, Verheul HMW.

J Neurooncol. 2017 Oct;135(1):183-192. doi: 10.1007/s11060-017-2564-z. Epub 2017 Jul 20.

19.

Web-Based Tailored Psychoeducation for Breast Cancer Patients at the Onset of the Survivorship Phase: A Multicenter Randomized Controlled Trial.

Admiraal JM, van der Velden AWG, Geerling JI, Burgerhof JGM, Bouma G, Walenkamp AME, de Vries EGE, Schröder CP, Reyners AKL.

J Pain Symptom Manage. 2017 Oct;54(4):466-475. doi: 10.1016/j.jpainsymman.2017.07.009. Epub 2017 Jul 13.

PMID:
28711750
20.

Web-based information and support for patients with a newly diagnosed neuroendocrine tumor: a feasibility study.

Bouma G, de Hosson LD, van Woerkom CE, van Essen H, de Bock GH, Admiraal JM, Reyners AKL, Walenkamp AME.

Support Care Cancer. 2017 Jul;25(7):2075-2083. doi: 10.1007/s00520-017-3598-7. Epub 2017 Feb 9.

21.

Cancer treatment induced metabolic syndrome: Improving outcome with lifestyle.

Westerink NL, Nuver J, Lefrandt JD, Vrieling AH, Gietema JA, Walenkamp AM.

Crit Rev Oncol Hematol. 2016 Dec;108:128-136. doi: 10.1016/j.critrevonc.2016.10.011. Epub 2016 Nov 3. Review.

22.

Novel insights into vascularization patterns and angiogenic factors in glioblastoma subclasses.

Conroy S, Wagemakers M, Walenkamp AM, Kruyt FA, den Dunnen WF.

J Neurooncol. 2017 Jan;131(1):11-20. doi: 10.1007/s11060-016-2269-8. Epub 2016 Sep 15.

23.

Bleomycin-Induced Pulmonary Changes on Restaging Computed Tomography Scans in Two Thirds of Testicular Cancer Patients Show No Correlation With Fibrosis Markers.

den Hollander MW, Westerink ND, Lubberts S, Bongaerts AH, Wolf RF, Altena R, Nuver J, Oosting SF, de Vries EG, Walenkamp AM, Meijer C, Gietema JA.

Oncologist. 2016 Aug;21(8):995-1001. doi: 10.1634/theoncologist.2015-0451. Epub 2016 Jun 21.

24.

89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease.

Oosting SF, van Asselt SJ, Brouwers AH, Bongaerts AH, Steinberg JD, de Jong JR, Lub-de Hooge MN, van der Horst-Schrivers AN, Walenkamp AM, Hoving EW, Sluiter WJ, Zonnenberg BA, de Vries EG, Links TP.

J Nucl Med. 2016 Aug;57(8):1244-50. doi: 10.2967/jnumed.115.167643. Epub 2016 May 12.

25.

Variation in the HFE gene is associated with the development of bleomycin-induced pulmonary toxicity in testicular cancer patients.

van der Schoot GGF, Westerink NL, Lubberts S, Nuver J, Zwart N, Walenkamp AME, Wempe JB, Meijer C, Gietema JA.

Eur J Cancer. 2016 May;59:134-141. doi: 10.1016/j.ejca.2016.02.013. Epub 2016 Mar 28.

PMID:
27033261
26.

Difference in CXCR4 expression between sporadic and VHL-related hemangioblastoma.

Kruizinga RC, van Marion DM, den Dunnen WF, de Groot JC, Hoving EW, Oosting SF, Timmer-Bosscha H, Derks RP, Cornelissen C, van der Luijt RB, Links TP, de Vries EG, Walenkamp AM.

Fam Cancer. 2016 Oct;15(4):607-16. doi: 10.1007/s10689-016-9879-3.

27.

Niacin (Vitamin B3) Supplementation in Patients with Serotonin-Producing Neuroendocrine Tumor.

Bouma G, van Faassen M, Kats-Ugurlu G, de Vries EG, Kema IP, Walenkamp AM.

Neuroendocrinology. 2016;103(5):489-94. doi: 10.1159/000440621. Epub 2015 Sep 4.

PMID:
26335390
28.

Studying cancer metastasis: Existing models, challenges and future perspectives.

van Marion DM, Domanska UM, Timmer-Bosscha H, Walenkamp AM.

Crit Rev Oncol Hematol. 2016 Jan;97:107-17. doi: 10.1016/j.critrevonc.2015.08.009. Epub 2015 Aug 10. Review.

PMID:
26321372
29.

Rectal and colon cancer: Not just a different anatomic site.

Tamas K, Walenkamp AM, de Vries EG, van Vugt MA, Beets-Tan RG, van Etten B, de Groot DJ, Hospers GA.

Cancer Treat Rev. 2015 Sep;41(8):671-9. doi: 10.1016/j.ctrv.2015.06.007. Epub 2015 Jun 28. Review.

PMID:
26145760
30.

TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET.

den Hollander MW, Bensch F, Glaudemans AW, Oude Munnink TH, Enting RH, den Dunnen WF, Heesters MA, Kruyt FA, Lub-de Hooge MN, Cees de Groot J, Pearlberg J, Gietema JA, de Vries EG, Walenkamp AM.

J Nucl Med. 2015 Sep;56(9):1310-4. doi: 10.2967/jnumed.115.154401. Epub 2015 Jul 1.

31.

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.

Beije N, Kraan J, Taal W, van der Holt B, Oosterkamp HM, Walenkamp AM, Beerepoot L, Hanse M, van Linde ME, Otten A, Vernhout RM, de Vos FY, Gratama JW, Sleijfer S, van den Bent MJ.

Br J Cancer. 2015 Jul 14;113(2):226-31. doi: 10.1038/bjc.2015.191. Epub 2015 Jun 4.

32.

The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.

Dirven L, van den Bent MJ, Bottomley A, van der Meer N, van der Holt B, Vos MJ, Walenkamp AM, Beerepoot LV, Hanse MC, Reijneveld JC, Otten A, de Vos FY, Smits M, Bromberg JE, Taal W, Taphoorn MJ; Dutch Neuro-Oncology Group (LWNO).

Eur J Cancer. 2015 Jul;51(10):1321-30. doi: 10.1016/j.ejca.2015.03.025. Epub 2015 Apr 17.

PMID:
25899986
33.

Microenvironment involved in FPR1 expression by human glioblastomas.

Boer JC, van Marion DM, Joseph JV, Kliphuis NM, Timmer-Bosscha H, van Strijp JA, de Vries EG, den Dunnen WF, Kruyt FA, Walenkamp AM.

J Neurooncol. 2015 May;123(1):53-63. doi: 10.1007/s11060-015-1777-2. Epub 2015 Apr 19.

34.

Internet-based support programs to alleviate psychosocial and physical symptoms in cancer patients: a literature analysis.

Bouma G, Admiraal JM, de Vries EG, Schröder CP, Walenkamp AM, Reyners AK.

Crit Rev Oncol Hematol. 2015 Jul;95(1):26-37. doi: 10.1016/j.critrevonc.2015.01.011. Epub 2015 Jan 31. Review.

PMID:
25701515
35.

CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment.

Tamas K, Domanska UM, van Dijk TH, Timmer-Bosscha H, Havenga K, Karrenbeld A, Sluiter WJ, Beukema JC, van Vugt MA, de Vries EG, Hospers GA, Walenkamp AM.

Curr Pharm Des. 2015;21(17):2276-83.

PMID:
25557636
36.

Subclassification of newly diagnosed glioblastomas through an immunohistochemical approach.

Conroy S, Kruyt FA, Joseph JV, Balasubramaniyan V, Bhat KP, Wagemakers M, Enting RH, Walenkamp AM, den Dunnen WF.

PLoS One. 2014 Dec 29;9(12):e115687. doi: 10.1371/journal.pone.0115687. eCollection 2014.

37.

Myocardial metastases on 6-[18F] fluoro-L-DOPA PET/CT: a retrospective analysis of 116 serotonin producing neuroendocrine tumour patients.

Noordzij W, van Beek AP, Tio RA, van der Horst-Schrivers AN, de Vries EG, van Ginkel B, Walenkamp AM, Glaudemans AW, Slart RH, Dierckx RA.

PLoS One. 2014 Nov 14;9(11):e112278. doi: 10.1371/journal.pone.0112278. eCollection 2014.

38.

TGF-β is an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion.

Joseph JV, Conroy S, Tomar T, Eggens-Meijer E, Bhat K, Copray S, Walenkamp AM, Boddeke E, Balasubramanyian V, Wagemakers M, den Dunnen WF, Kruyt FA.

Cell Death Dis. 2014 Oct 2;5:e1443. doi: 10.1038/cddis.2014.395.

39.

Dopamine and serotonin regulate tumor behavior by affecting angiogenesis.

Peters MA, Walenkamp AM, Kema IP, Meijer C, de Vries EG, Oosting SF.

Drug Resist Updat. 2014 Oct-Dec;17(4-6):96-104. doi: 10.1016/j.drup.2014.09.001. Epub 2014 Sep 22. Review.

PMID:
25269824
40.

CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model.

Domanska UM, Boer JC, Timmer-Bosscha H, van Vugt MA, Hoving HD, Kliphuis NM, Rosati S, van der Poel HG, de Jong IJ, de Vries EG, Walenkamp AM.

Clin Exp Metastasis. 2014 Oct;31(7):829-39. doi: 10.1007/s10585-014-9673-2. Epub 2014 Aug 26.

PMID:
25154297
41.

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B, van den Bent MJ.

Lancet Oncol. 2014 Aug;15(9):943-53. doi: 10.1016/S1470-2045(14)70314-6. Epub 2014 Jul 15.

PMID:
25035291
42.

Recruitment of bone marrow derived cells during anti-angiogenic therapy in GBM: the potential of combination strategies.

Boer JC, Walenkamp AM, den Dunnen WF.

Crit Rev Oncol Hematol. 2014 Oct;92(1):38-48. doi: 10.1016/j.critrevonc.2014.05.001. Epub 2014 May 10. Review.

PMID:
24933160
43.

Everolimus Reduces (89)Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors.

van Asselt SJ, Oosting SF, Brouwers AH, Bongaerts AH, de Jong JR, Lub-de Hooge MN, Oude Munnink TH, Fiebrich HB, Sluiter WJ, Links TP, Walenkamp AM, de Vries EG.

J Nucl Med. 2014 Jul;55(7):1087-92. doi: 10.2967/jnumed.113.129056. Epub 2014 May 1.

44.

Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity.

Gooden MJ, Wiersma VR, Boerma A, Leffers N, Boezen HM, ten Hoor KA, Hollema H, Walenkamp AM, Daemen T, Nijman HW, Bremer E.

Br J Cancer. 2014 Mar 18;110(6):1535-44. doi: 10.1038/bjc.2014.55. Epub 2014 Feb 11.

45.

Calculating optimal surveillance for detection of von Hippel-Lindau-related manifestations.

Kruizinga RC, Sluiter WJ, de Vries EG, Zonnenberg BA, Lips CJ, van der Horst-Schrivers AN, Walenkamp AM, Links TP.

Endocr Relat Cancer. 2013 Dec 20;21(1):63-71. doi: 10.1530/ERC-13-0308. Print 2014 Feb.

PMID:
24132471
46.

Placental growth factor (PlGF)-specific uptake in tumor microenvironment of 89Zr-labeled PlGF antibody RO5323441.

Oude Munnink TH, Tamas KR, Lub-de Hooge MN, Vedelaar SR, Timmer-Bosscha H, Walenkamp AM, Weidner KM, Herting F, Tessier J, de Vries EG.

J Nucl Med. 2013 Jun;54(6):929-35. doi: 10.2967/jnumed.112.112086. Epub 2013 Apr 26.

47.

[⁹⁹mTc]O₂-AMD3100 as a SPECT tracer for CXCR4 receptor imaging.

Hartimath SV, Domanska UM, Walenkamp AM, Rudi A J O D, de Vries EF.

Nucl Med Biol. 2013 May;40(4):507-17. doi: 10.1016/j.nucmedbio.2013.02.003. Epub 2013 Mar 20.

48.

Pancreatic cyst development: insights from von Hippel-Lindau disease.

van Asselt SJ, de Vries EG, van Dullemen HM, Brouwers AH, Walenkamp AM, Giles RH, Links TP.

Cilia. 2013 Feb 5;2(1):3. doi: 10.1186/2046-2530-2-3.

49.

Inhibition of formyl peptide receptor in high-grade astrocytoma by CHemotaxis Inhibitory Protein of S. aureus.

Boer JC, Domanska UM, Timmer-Bosscha H, Boer IG, de Haas CJ, Joseph JV, Kruyt FA, de Vries EG, den Dunnen WF, van Strijp JA, Walenkamp AM.

Br J Cancer. 2013 Feb 19;108(3):587-96. doi: 10.1038/bjc.2012.603. Epub 2013 Jan 15.

50.

Value of 11C-methionine PET in imaging brain tumours and metastases.

Glaudemans AW, Enting RH, Heesters MA, Dierckx RA, van Rheenen RW, Walenkamp AM, Slart RH.

Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):615-35. doi: 10.1007/s00259-012-2295-5. Epub 2012 Dec 12. Review.

PMID:
23232505

Supplemental Content

Loading ...
Support Center